Promising Results for Candel Therapeutics' Non-Metastatic Pancreatic Cancer Treatment

Thursday, 4 April 2024, 12:36

Candel Therapeutics has released positive interim data for CAN-2409 in a mid-stage trial for pancreatic cancer. The data shows improved overall survival rates at 24 and 36 months, indicating potential efficacy in non-metastatic pancreatic cancer treatment. These results suggest a promising future for CAN-2409 as a viable treatment option for pancreatic cancer patients.
LivaRava Finance Meta Image
Promising Results for Candel Therapeutics' Non-Metastatic Pancreatic Cancer Treatment

Promising Interim Data for CAN-2409

Candel Therapeutics has announced positive results for its non-metastatic pancreatic cancer treatment, CAN-2409. The interim data from a mid-stage trial indicates improved overall survival rates at 24 and 36 months.

Impact on Pancreatic Cancer Treatment

  • Improved Survival Rates: Results show promising outcomes for patients with non-metastatic pancreatic cancer.
  • Potential Treatment Efficacy: CAN-2409 demonstrates potential as an effective treatment option.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe